Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 3/20 | 0.39 |
| ▸ | SHMT1 | P34896 | 2/20 | 0.37 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | ECE1 | P42892 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2348343 | 0.90 | ANO1 (0.38) | ANO1SHMT1SHMT2L3MBTL1ALDH1A1 | |
| SCHEMBL15466678 | 0.89 | ANO1 (0.38) | ANO1SHMT1SHMT2L3MBTL1P2RX7 | |
| SCHEMBL2354533 | 0.88 | ANO1 (0.37) | ANO1SHMT1SHMT2TRPV1SLC6A3 | |
| SCHEMBL2353770 | 0.87 | ACACB (0.39) | ANO1SHMT1SHMT2SLC6A3 | |
| SCHEMBL12457529 | 0.87 | ACACB (0.39) | ANO1SHMT1SHMT2SLC6A3 | |
| SCHEMBL14689807 | 0.87 | ACACB (0.39) | ANO1SHMT1SHMT2SLC6A3 | |
| SCHEMBL12458145 | 0.86 | ANO1 (0.38) | ANO1SHMT1SHMT2SLC6A3LPAR1 | |
| SCHEMBL2350931 | 0.86 | ANO1 (0.38) | ANO1SHMT1SHMT2SLC6A3LPAR1 | |
| SCHEMBL14689724 | 0.86 | ANO1 (0.38) | ANO1SHMT1SHMT2SLC6A3LPAR1 | |
| SCHEMBL14689906 | 0.85 | ACACB (0.40) | ANO1SHMT1SHMT2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| EP-2536686-A1 | CYCLIC KETO-ENOLS FOR THERAPY | Bayer Intellectual Property GmbH (DE) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011098433-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011098433-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | AKR1B1, AKR1C3, AKR1A1 | ANO1 3557/4885SHMT1 1267/4885SHMT2 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.